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Sepsis is a serious health condition worldwide, affecting more than 30 million people
globally each year. Blood culture (BC) is generally used to diagnose sepsis because of the
low quantity of microbes occurring in the blood during such infections. However, ∼50%
of bloodstream infections (BSI) give negative BC, this figure being higher for sepsis, which
delays the start of appropriate antimicrobial therapy. This prospective study evaluated a
multiplex real-time polymerase chain reaction, the MagicplexTM Sepsis test (MP), for the
detection of pathogens from whole blood, comparing it to routine BC. We analyzed 809
blood samples from 636 adult patients, with 132/809 (16.3%) of the samples positive
for one or more relevant microorganism according to BC and/or MP. The sensitivity and
specificity of MP were 29 and 95%, respectively, while the level of agreement between
BC and MP was 87%. The rate of contaminated samples was higher for BC (10%)
than MP (4.8%) (P < 0.001). Patients with only MP-positive samples were more likely
to be on antimicrobial treatment (47%) than those with only BC-positive samples (18%)
(P = 0.002). In summary, the MP test could be useful in some clinical setting, such
as among patients on antibiotic therapy. Nevertheless, a low sensitivity demonstrated
impairs its use as a part of a routine diagnostic algorithm.
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INTRODUCTION
The World Health Organization (WHO) in 2017 adopted a resolution on sepsis: “improving the
prevention, diagnosis and clinical management of sepsis” (World Health Organization, 2018).
Blood culture (BC) is generally used to diagnose sepsis because of the low quantity of microbes
occurring in the blood during such infections. However,∼50% of bloodstream infections (BSI) give
negative BC, this figure being higher for sepsis, which delays the start of appropriate antimicrobial
therapy and consequently results in worse outcomes and higher mortality rates (Kumar et al., 2006;
Ferrer et al., 2014). Prompt microbiological diagnosis enables a more appropriate antimicrobial
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treatment than the empirical combination of broad-spectrum
antibiotics that have negative effects such as an increased
prevalence of resistant pathogens (Candel et al., 2018). The
microbial diagnosis of sepsis by BC has two main advantages:
first, it allows the growth of very small numbers of the
microorganism, which is important since the concentration of
bacteria in the blood of septic adult patients is usually low (<10
CFU/mL) (Yagupsky and Nolte, 1990); second, this technique
allows the isolation of pathogens and, hence, antimicrobial
susceptibility testing can be performed. However, BC also has
limitations that do not make it an ideal gold standard test,
including the long time required for growth detection, the
frequent false negative results in patients receiving antimicrobial
therapy, and the inability to detect fastidious microorganisms
(Sinha et al., 2018) which can delay the initiation of an
adequate antimicrobial therapy and consequently results in worse
outcomes and higher mortality rates (Kumar et al., 2006; Ferrer
et al., 2014). Molecular tests offer important advantages over BC
that could improve the diagnosis of BSI, such as the lower amount
of time taken to obtain results by working directly from blood.
In addition, the low detection limits of molecular assays might
make them more sensitive than BC, enabling the detection of
fastidious, non-viable or non-culturable microorganisms, even
from patients on antibiotic treatment (Fenollar and Raoult, 2007;
Leitner et al., 2013; Sinha et al., 2018).
Another advantage of molecular assays is the ability to
detect some specific resistance markers, which can provide
important information for better treatment. Moreover, the
rapid identification of the microorganism can be used to infer
antimicrobial susceptibility according to local epidemiology.
The MagicplexTM Sepsis test (MP) (Seegene, Seoul, South
Korea) is a multiplex real-time polymerase chain reaction (PCR)
that detects more than 90 microorganisms at the genus level (73
Gram-positive bacteria, 12 Gram-negative bacteria and 6 fungi),
27 at the species level and 3 drug-resistant genes (mecA, vanA,
and vanB)within 6 h. In this study, we evaluated the ability of the
MP test to rapidly detect pathogens causing BSI in adult patients
from whole blood compared to conventional BC.
METHODS
Setting, Data, and Sample Collection
The study was approved by the Ethics Committee of the
Hospital Clinic of Barcelona (study no. 2011/6613). Written
informed consent was waived because of the non-interventional
study design.
Paired BC and 1ml samples of whole blood in an EDTA
tube were obtained from adult patients (≥18 years old) from
the Hospital Clinic of Barcelona, a 700-bed university hospital
in Barcelona, Spain, from May to September 2011.
Samples were obtained from patients with suspected BSI and
who met the criteria for BC collection. Samples were processed
in parallel by MP and BC. Blood samples for MP and BC were
obtained simultaneously from the same catheter or venipuncture.
For each case, additional clinical data about ongoing antibiotic
treatment, the suspected source of infection, as well as the results
of other microbiological tests were collected.
Routine Microbiological Techniques
BC was incubated in a Bactec 9240 R© (Becton Dickinson, MD,
USA) for a maximum of 5 days. The following bottles were used:
the resin-containing BACTEC Plus Aerobic/F and BACTEC
Plus Anaerobic/F, and the non-resin-containing BACTEC
Standard/10 Aerobic/F and BACTEC Lytic/10 Anaerobic/F.
For positive samples, Gram staining and culturing on solid
media were performed. Microorganisms were identified using
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bremen,
Germany). Routine susceptibility testing included the Phoenix
TM
system (Becton Dickinson, MD, USA), Etest (AB bioMérieux),
microdilution (Sensititre, Trek Diagnostic Systems, Inc.,
Westlake, Ohio, USA) and disc diffusion tests, depending on the
pathogen isolated. Determination of the isolates as contaminants
or pathogens was achieved by combining the clinical setting,
pathogenicity of the isolated microorganisms and the number of
positive BC bottles in the case of potential skin contaminants,
such as coagulase-negative staphylococci (CoNS). CoNS were
considered pathogens if the same species was detected in both
sets of BC showing the same antimicrobial susceptibility pattern.
Samples with positive BC for pathogens not included in the MP
panel were excluded from the analysis.
The MagicplexTM Sepsis Test (MP)
Blood samples were initially pre-treated with the Seegene Blood
Pathogen Kit
TM
, according to the manufacturer’s instructions.
This pre-treatment included the following steps: lysis of human
cells with CM buffer, degradation of released DNA with
MolDNase B, concentration by centrifugation of microorganisms
and, finally, lysis of cells and release of nucleic acid. Bacterial
DNA was automatically extracted and purified with the
SeePrep12TM extractor (Seegene). Amplification, screening and
identification were performed following the manufacturer’s
instructions. Each sample was first processed by two conventional
PCRs performed in two separate tubes: one for the detection of
Gram-positive bacteria and resistance genes, and the other for
Gram-negative bacteria (GNB) and fungi (Figure 1).
For this step the thermal cycler System 9700, Applied
Biosystems was used. The first real-time PCR for screening was
performed in three separate tubes, allowing the identification
of pathogens at the genus or group level: Streptococcus spp.,
Staphylococcus spp., Enterococcus spp., GNB group A or B, fungi
and 3 resistance genes (vanA, vanB, and mecA). For positive
results, the second real-time PCR was carried out, allowing the
identification of 27 pathogens at the species level, including
3 Streptococcus spp. (Streptococcus pneumoniae, Streptococcus
agalactiae and Streptococcus pyogenes), 3 Enterococcus spp.
(Enterococcus faecalis, Enterococcus faecium and Enterococcus
gallinarum), 3 Staphylococcus spp. (Staphylococcus epidermidis,
Staphylococcus haemolyticus and Staphylococcus aureus), 6
GNB from group A (Pseudomonas aeruginosa, Acinetobacter
baumannii, Stenotrophomonas maltophilia, Serratia marcescens,
Bacteroides fragilis, and Salmonella typhi), 6 GNB from
group B (Klebsiella pneumoniae, Klebsiella oxytoca, Proteus
mirabilis, Escherichia coli, Enterobacter cloacae, and Enterobacter
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FIGURE 1 | Process of MagicplexTM sepsis.
aerogenes), and 6 fungi (Candida albicans, Candida parapsilosis,
Candida glabrata, Candida tropicalis, Candida krusei, and
Aspergillus fumigatus). The real-time PCR were performed using
the Cepheid SmartCycler.
The Seegene Viewer software was used to interpret the results,
which were available within 6 h. All the samples were stored at
2–8◦C and processed within 24 h after collection.
MP samples positive for CoNS were considered to be true
positives if the same microorganism was detected in two sets
of BC. Samples that were positive according to MP in the
first real-time PCR screening and identified only at the group
level (e.g., GNB group A), but negative in the second real
time-PCR were considered negative according to MP. To avoid
confusing calculation in sensitivity and specificity we consider
samples with only contaminants detected by MP and/or BC
as negative. Internal control is included in each PCR step.
Microorganisms identified by MP only at the genus level, such as
Staphylococcus spp. and Streptococcus spp., were considered to be
contaminants if the BC was negative or positive for staphylococci
or streptococci that could be identified by MP at the
species level.
Statistical Analysis
Categorical variables were compared using the chi-square test.
To calculate the yield of the test, we analyzed sensitivity and
specificity, and predictive values. All statistical comparisons were
two-sided hypothesis tests, and the significance level was set
at 0.05. All confidence intervals (CIs) were two-sided at 95%
confidence level. All analyses were performed with IBM SPSS
Statistics 22.0 (Armonk, New York).
RESULTS
A total of 809 samples from 636 adult patients were collected
and analyzed. Among the samples, 435 out of 809 (54%)
were from the emergency wards, 197 (24%) from intensive
care units (ICUs) and surgery, 159 (20%) from oncology
and hematology wards, and 18 (2%) from other medical
wards. The average age of patients was 56.7 ± 5.6; 43%
were females.
A total of 140 pathogens were detected among 132 positive
samples (Table 1). E. coli was the most frequently detected
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TABLE 1 | Comparison of microbiological results between BC and MP.
Pathogens detected Positive only BC Positive only MP Positive both methods Total, n (%) Prevalence among 809 samples, %
Escherichia coli 27 15 5 47 (34) 5.8
CoNS 7 0 9 16 (11) 2
Candida spp. 9 2 3 14 (10) 1.7
Staphylococcus aureus 2 7 4 13 (9) 1.6
Enterococcus faecalis 5 3 3 11 (8) 1.4
Pseudomonas aeruginosa 6 2 1 9 (6) 1.1
Klebsiella pneumoniae 6 2 1 9 (6) 1.1
Streptococcus spp. 3a 2b 1c 6 (4) 0.7
Enterobacter cloacae 3 1 0 4 (3) 0.5
Enterococcus faecium 2 0 1 3 (2) 0.4
Acinetobacter spp. 1 2 0 3 (2) 0.4
Serratia marcescens 1 1 0 2 (2) 0.2
Enterococcus gallinarum 0 1 0 1 (1) 0.1
Klebsiella oxytoca 0 1 0 1 (1) 0.1
Stenotrophomonas maltophilia 0 1 0 1 (1) 0.1
Total, n (%) 72 (51) 40 (29) 28 (20) 140 (100)
BC, blood culture; MP, MagicPlex assay; CoNs, coagulase-negative staphylococci.
aStreptococci of viridians group (S. anginosus and S. gordonii) and one S. agalactiae.
bOne S. agalactiae and one S. pneumoniae.
cS. constellatus.
pathogen (47/140, 33.6%), followed by CoNS (16/140, 11.4%),
Candida spp. (14/140, 10%), and S. aureus (13/140, 9.3%).
BC identified 3 mixed infections: E. cloacae plus K.
pneumoniae, C. glabrata plus S. haemolyticus, and P. aeruginosa
plus S. epidermidis. MP detected 4 mixed infections: S. agalactiae
plus S. aureus, E. coli plus S. epidermidis, P. aeruginosa plus S.
marcescens, and E. coli plus E. gallinarum. One mixed infection
(E. faecium plus S. haemolyticus) was identified by both methods.
Three mecA genes were detected among the 9 pathogenic
CoNS identified by the two methods. Routine susceptibility
testing detected 7 methicillin-resistant CoNS and 2 methicillin-
susceptible strains. Only one vanB resistance marker was
detected in a sample positive for E. faecalis only according to
MP and not BC. Therefore, this result remained unconfirmed.
No additional BC or other microbiological samples positive for
E. faecalis were obtained from this patient.
As shown in Table 2, samples with microbial contaminants
were more frequently observed with BC than MP: 81/809 (10%)
vs. 39/809 (4.8%) (P <0.001), respectively.
Blood samples in which only microbial contaminants were
detected were considered as negative for further analysis. As a
result, 132/809 (16.3%) of the samples were considered positive
for one or more relevant microorganism by BC and/or MP. The
level of agreement between BC and MP was 87.1% (705/809).
Regarding the 28 samples positive according to both methods,
the same pathogen was identified in 27 of the cases, with
the remaining one sample showing inconsistent results: E. coli
detected by MP and E. faecium by BC. The rate of positive results
was higher for BC (96/809, 11.9%) than MP (64/809, 7.9%).
Considered BC the gold standard and considering negative
the samples with only contaminants detected, the sensitivity,









MP-positive 28 31 5 64
MP-negative 62 574 70 706
MP-contaminated 6 27 6 39
Total 96 632 81 809
BC, blood culture; MP, MagicPlex assay.
specificity, positive predictive value and negative predictive value
of MP were 29.2% (95% CI, 20.6–39.5), 95% (95% CI, 93–
96.4), 43.8% (95% CI, 31.6–56.7), and 90.9% (95% CI, 88.5–
92.8), respectively.
Additional clinical information, including underlying disease
and the antibiotic or antifungal therapy administered on the
day of sampling, was recorded for the patients with 36 MP-
positive and BC-negative or contaminated results (Table 3).
When comparing the percentage of patients with undergoing
antimicrobial treatment at the time of sample collection between
three groups: only BC-positive (12/68, 17.6%), only MP-positive
(17/36, 47.2%), and BC and MP-positive (8/28, 28.6%), there was
significantly higher number of patients receiving antimicrobials
in the group of only MP-positive (P = 0.002). Interestingly, 3
of the 17 patients with only an MP-positive sample had a BC
positive for the same microorganism in the previous days, while
in 5 patients, other microbiological samples were positive for the
pathogen detected by MP.
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TABLE 3 | Additional information from 36 patients with MP-positive and BC-negative results.
Setting MP result Clinical condition Other microbiological tests







Klebsiella oxytoca Self-limiting fever after removal of a Kehrs
tube in a liver transplant patient
– –
Escherichia coli Subarachnoid hemorrhage Control BC 3
days after catheter-related Pseudomonas
aeruginosa bacteremia
– Ciprofloxacin
Escherichia coli Necrotizing fasciitis BC and wound swab culture
positive for E. coli 3 days before
sampling
Meropenem





Acute myeloid leukemia with neutropenic
fever without a clinical focus
– Piperacillin-tazobactam,
Vancomycin
Candida parapsilosis K. pneumoniae bacteremia secondary to
mesenteric vein thrombosis in a cirrhotic
patient Nosocomial pneumonia due to
S.aureus and Acinetobacter baumannii
3 bronchial washing samples
positive for Candida spp.
Fluconazole
Escherichia coli Septic shock due to S. aureus cellulitis in a
cirrhotic patient. Ascites decompensation
Wound smear positive for S.
aureus
Ceftazidime and Tigecycline
Escherichia coli Acute necrotizing pancreatitis with
peripancreatic abscess
– Meropenem
Staphylococcus aureus Superinfection of Pulmonary contusion in
a polytrauma patient
Tracheal aspirate positive for S.
aureus 2 days before sampling
Levofloxacin
Escherichia coli Colonic perforation post-nephrectomy – Piperacillin-tazobactam
Enterobacter cloacae Intestinal obstruction and abdominal
sepsis secondary to inguinal hernia
– Levofloxacin
Acinetobacter baumannii Post-operative fever (liver resection 48 h
before sampling)
– –
Acinetobacter baumannii Thoracic empyema in a cirrhotic patient – –
Staphylococcus aureus Hepatocellular carcinoma. Metabolic
decompensation of diabetes mellitus
– –
Escherichia coli Urinary tract infection (UTI) – Ciprofloxacin and
Ceftriaxone
Candida parapsilosis Post-operative intraabdominal abscess – –
Emergency department
(n = 15)
Escherichia coli UTI – –
Staphylococcus aureus Stroke. Bronchoaspiration in a patient with






Escherichia coli HIV patient with prosthetic aortic valve
with progressive prurigo nodularis
– Amoxicillin/clavulanic acid
Escherichia coli Fever during hemodialysis Urine culture positive for E. coli Amoxicillin/clavulanic acid
Escherichia coli Acute exacerbation of chronic obstructive
pulmonary disease (COPD)
Sputum sample positive for E.
coli
–






Staphylococcus aureus Pneumonia – –
Staphylococcus
aureus
UTI in a patient with permanent bladder
catheter
– Amoxicillin/clavulanic acid
Pseudomonas aeruginosa Acute exacerbation of Crohn’s disease. – –
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TABLE 3 | Continued
Setting MP result Clinical condition Other microbiological tests







Community-acquired UTI – –
Escherichia coli Acute exacerbation of COPD – –
Klebsiella pneumoniae Pneumocystis carinii pneumonia in an










Escherichia coli Acute myeloid leukemia. Neutropenic fever – –
Escherichia coli Stem cell transplanted patient due to
acute myeloid leukemia. Neutropenic fever
– –
Escherichia coli Fever in a patient with acute lymphoblastic
leukemia
– Meropenem
Enterococcus faecalis Catheter-related blood stream infection in
a patient transplanted due to acute
myeloid leukemia
BC positive for E. faecalis 6 days
before sampling
Daptomycin
ICU, intensive care unit; BC, blood culture; MP, MagicPlex assay.
aOnly antimicrobial/antifungal therapy potentially effective against pathogen detected and initiated before sampling.
DISCUSSION
Several molecular assays have been tested for the direct molecular
identification of pathogens in blood samples (Lehmann et al.,
2008; Wellinghausen et al., 2009; Bloos et al., 2012; Grif et al.,
2012; Loonen et al., 2013; Nieman et al., 2016) However, few
studies have focused on commercially available PCR-based tests
other than the SeptiFast test for the detection of BSI (Kühn et al.,
2011; Fitting et al., 2012). Recently, T2 magnetic resonance assay
was evaluated to detect Candida spp. and some bacteria in whole
blood (Mylonakis et al., 2015; Snyder et al., 2017; Peker et al.,
2018). In the present study, we evaluated the MagicplexTM Sepsis
test (MP), comparing it with conventional BC. We observed
that MP showed a sensitivity and specificity of 29.2 and 95%,
respectively. Only a few studies have evaluated the sensitivity
and specificity of MP (Carrara et al., 2013; Loonen et al., 2013;
Ljungström et al., 2015; Denina et al., 2016; Ziegler et al., 2016).
Carrara et al. (2013), assessing 267 patients from ICU, emergency
and hematology wards, reported an overall sensitivity of 65% for
MP compared with 41% for BC. However, the authors calculated
the sensitivities and specificities using a reference standard in
which clinical data and other cultures were added to the BC
results to see if a positive MP result represented a true BSI
or not. Loonen et al. (2013), investigating 125 patients from
the emergency department, reported a sensitivity of 37% and
a positive predictive value (PPV) of 30% for MP, the low PPV
resulting from many of the samples being positive for CoNS
according to MP. Ljungström et al. (2015), analyzing samples
from 375 patients with suspected sepsis collected from emergency
wards, excluded suspected contaminants such as CoNS. They
reported a sensitivity of 64% and specificity of 96% for MP.
However, if they had included all the MP and BC results, the
sensitivity of MP would have been 38%, PPV 17%, and specificity
65%. Taking into account all these results, the MP test could
be useful in some clinical setting, such as among patients with
undergoing antimicrobial treatment and negative blood cultures.
Nevertheless, a low sensitivity demonstrated limits its use as
a part of routine diagnostic algorithm. The low sensitivity of
MP is probably due to the low bacterial concentration in whole
blood and the low sample volume of 1ml used. There are
several strategies intended to improve bacterial recovery, such
as removing or significantly reducing the amount of human
DNA present in the whole blood sample. Nevertheless, this step
is already included in the MP and SepsiTest assays. Another
possibility is to introduce an additional incubation step prior
to extraction (Serra et al., 2012). Although this approach can
increase microbial concentrations, it lengthens the whole process
and compromises the main advantage of the molecular assays,
which is the rapid procurement of results. Another strategy is to
increase the initial volume of the blood sample (>1ml) (Hansen
et al., 2009), which has been reported to give promising results
and greatly improve the detection rates of PCR-based assays
(Loonen et al., 2013) or increase the amount of bacterial DNA,
as shown by Trung et al. (2016).
We observed 36 samples that were positive according to MP
and negative according to BC. This could have been due to
the fact that almost half of these samples were obtained from
patients on antibiotic treatment, which could explain the negative
BC results. Unfortunately, the data about the start time and
duration of antimicrobial treatment was not collected; therefore
more detailed analysis of the treatment impact on BC and MP
positivity could not be performed. The presence of cell-free
DNA or non-viable microorganisms or even contaminating DNA
could explain the other 19 discordant results (Opota et al., 2015).
Importantly, MP detected 5 out of the 14 Candida spp. and
11 out of the 13 S. aureus isolates in our study. Early detection
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of these two pathogens is essential due to the high mortality
rates and risk of haematogenous complications associated with
these microbes. In addition, some Candida requires a longer
time for growth in BC than other pathogens, delaying the
initiation of treatment by several days. Candida spp. was
the third most frequently occurring pathogen detected in our
study. As expected, most of the positive samples were obtained
from ICU patients. We detected a small number of resistance
genes. Although the three mecA genes detected by MP were
confirmed by routine susceptibility testing, in four cases of CoNS
methicillin-resistant by routine susceptibility testing mecA gene
was not detected by MP. Furthermore, the only vanB-positive E.
faecalis detected by MP was not isolated by BC. Therefore, the
accuracy of MP in detecting resistance genes should be further
evaluated and probably is necessary the second molecular assay
to confirm discordant results due to low predictor value of some
phenotypic testing for detection of methicillin resistance.
Despite the many advantages of molecular assays, these tests
have several important limitations. First, these methods require
specialized equipment and technical experience and are usually
expensive. The MP test also has several manual steps that make
it laborious and increase the risk of possible contamination.
Moreover, its low sensitivity makes its implementation as a
routine test difficult in clinical microbiology laboratories. Finally,
the sensitivity and specificity of molecular assays vary according
to the test, the extraction method, the algorithm used to evaluate
the results, the comparative method and the study population.
Data published to date support the use of PCR-based tests for
specific groups of patients, such as critically ill patients in ICU,
those with suspected candidaemia or patients receiving broad-
spectrum antibiotics (von Lilienfeld-Toal et al., 2009; Bravo et al.,
2011). There is no consensus about the interpretation of BC-
negative and PCR-positive results (low pathogen concentrations,
non-viable bacteria and DNAemia, etc.). Further studies are
needed to evaluate the role of newmolecular assays in the routine
microbiological diagnosis of BSI. Themain strengths of our study
are: the higher sample number comparing with previous reports;
patients included were not only from emergency departments but
also from ICU and oncology/hematology; clinical conditions and
antimicrobial treatment of patients with positive results detected
only by PCR was investigated.
The main limitation of this study is that discordant only MP
positive results were considered as false positive due to the use of
BC as comparator. BC lacks sensitivity and the second molecular
assay should be used to evaluate discordant results.
In conclusion, sepsis is a time-dependent disease that
requires early diagnosis and prompt appropriate treatment
to improve prognosis. The MP assay provides results within
6 h, thereby significantly reducing the amount of time for
diagnosis and seems to be especially useful in patients on
antimicrobial treatment. Nevertheless, the assay has to be
optimized, mainly to improve the sensitivity and also including
other significant microorganisms within the panel. Greater
automation is necessary to facilitate introduction of the assay
into routine laboratory workflow and to reduce turnaround time.
Furthermore, the microbial detection limits of the molecular
assay need to be improved, probably by new extraction protocols
and greater sample volumes to improve the positive and negative
predictive power so that it can be a useful tool in clinical practice,
especially regarding its impact on antibiotic use.
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